Research presented Wednesday at the 2014 International Alzheimer's Association International Conference shows that a new drug may help slow early stages of the disease.
Scientists followed more than 400 patients with mild-to-moderate Alzheimer's disease for 73 weeks. Some patients were given a high dose of the drug, crenezumab, intravenously every four weeks. Others received a low dose injection of the drug under the skin every other week. And the rest were given a placebo.
Researchers say in milder forms of the disease, the high-dose IV form of the drug did show evidence of slowing the decline of cognitive abilities.